-
Something wrong with this record ?
Comparative analysis of clinicopathological correlations of cyclooxygenase-2 expression in resectable pancreatic cancer
Marketa Hermanova, Petr Karasek, Jiri Tomasek, Jiri Lenz, Jiri Jarkovsky, Petr Dite
Language English Country Taiwan
Document type Comparative Study, Journal Article, Research Support, Non-U.S. Gov't
Grant support
NR9295
MZ0
CEP Register
Digital library NLK
Full text - Article
Source
NLK
Free Medical Journals
from 1998
Freely Accessible Science Journals
from 1998
PubMed Central
from 1997
Europe PubMed Central
from 1997
- MeSH
- Cyclooxygenase 2 biosynthesis MeSH
- Adult MeSH
- Immunohistochemistry methods MeSH
- Middle Aged MeSH
- Humans MeSH
- Antibodies, Monoclonal metabolism MeSH
- Pancreatic Neoplasms enzymology surgery MeSH
- Prognosis MeSH
- Proportional Hazards Models MeSH
- Gene Expression Regulation, Enzymologic MeSH
- Gene Expression Regulation, Neoplastic MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Pancreatic Ducts enzymology pathology MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Comparative Study MeSH
AIM: To perform a comparative analysis of clinicopathological correlations of cyclooxygenase-2 (COX-2) expression in pancreatic cancer, examined by monoclonal and polyclonal antibodies. METHODS: The COX-2 expression in 85 resection specimens of pancreatic ductal adenocarcinoma was immunohistochemically examined using both monoclonal and polyclonal antibodies. The final immunoscores were obtained by multiplying the percentage of positive cells with the numeric score reflecting the staining intensity. COX-2 expression levels were classified into three categories (0, 1+, and 2+) and the clinicopathological correlations were statistically evaluated and analyzed. RESULTS: The positive tumor expression rates of COX-2 were 80.5% using monoclonal antibody and 69.4% using polyclonal antibody. In the Kaplan-Meier analysis, no significant correlations were found between levels of COX-2 expression and overall survival (OS), but trends to longer OS were found in COX-2 negative cases using monoclonal antibody. Significantly longer disease free survival was revealed in COX-2 negative cases using monoclonal antibody (P = 0.019). No correlations between COX-2 expression levels and grade (G), tumor (T) status and nodal (N) status were demonstrated. Low histological grade showed a strong association with a longer OS (P < 0.001). Correlation of survival and T status revealed a shorter OS in T3 tumors, but the results reached only marginal statistical significance (P = 0.070). In the multivariate Cox proportional hazards regression model, histological grade, T and N status remained valuable predictors of a worse survival with borderline significance for T [hazards ratio (HR) = 4.18 for G (if G = 3, P < 0.001); HR = 1.64 for T (if T = 3, P = 0.065); HR = 2.53 for N (if N = 1, P = 0.006)]. Higher grade, T or N status was associated with a worse OS. CONCLUSION: The immunohistochemically assessed level of COX-2 expression does not seem to represent a valuable independent prognostic factor and is not superior to the conventional prognostic factors.
Department of Complex Oncology Care Masaryk Memorial Cancer Institute Brno Czech Republic
Institute of Biostatistics and Analyses Masaryk University Brno Czech Republic
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc12025786
- 003
- CZ-PrNML
- 005
- 20200429134614.0
- 007
- ta
- 008
- 120817s2010 ch f 000 0#eng||
- 009
- AR
- 024 7_
- $a 10.3748/wjg.v16.i15.1879 $2 doi
- 035 __
- $a (PubMed)20397266
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ch
- 100 1_
- $a Hermanová, Markéta $7 xx0073982 $u First Department of Pathologic Anatomy, Medical Faculty of Masaryk University and St. Anne's University Hospital, Brno, Czech Republic. marketa.hermanova@fnusa.cz
- 245 10
- $a Comparative analysis of clinicopathological correlations of cyclooxygenase-2 expression in resectable pancreatic cancer / $c Marketa Hermanova, Petr Karasek, Jiri Tomasek, Jiri Lenz, Jiri Jarkovsky, Petr Dite
- 520 9_
- $a AIM: To perform a comparative analysis of clinicopathological correlations of cyclooxygenase-2 (COX-2) expression in pancreatic cancer, examined by monoclonal and polyclonal antibodies. METHODS: The COX-2 expression in 85 resection specimens of pancreatic ductal adenocarcinoma was immunohistochemically examined using both monoclonal and polyclonal antibodies. The final immunoscores were obtained by multiplying the percentage of positive cells with the numeric score reflecting the staining intensity. COX-2 expression levels were classified into three categories (0, 1+, and 2+) and the clinicopathological correlations were statistically evaluated and analyzed. RESULTS: The positive tumor expression rates of COX-2 were 80.5% using monoclonal antibody and 69.4% using polyclonal antibody. In the Kaplan-Meier analysis, no significant correlations were found between levels of COX-2 expression and overall survival (OS), but trends to longer OS were found in COX-2 negative cases using monoclonal antibody. Significantly longer disease free survival was revealed in COX-2 negative cases using monoclonal antibody (P = 0.019). No correlations between COX-2 expression levels and grade (G), tumor (T) status and nodal (N) status were demonstrated. Low histological grade showed a strong association with a longer OS (P < 0.001). Correlation of survival and T status revealed a shorter OS in T3 tumors, but the results reached only marginal statistical significance (P = 0.070). In the multivariate Cox proportional hazards regression model, histological grade, T and N status remained valuable predictors of a worse survival with borderline significance for T [hazards ratio (HR) = 4.18 for G (if G = 3, P < 0.001); HR = 1.64 for T (if T = 3, P = 0.065); HR = 2.53 for N (if N = 1, P = 0.006)]. Higher grade, T or N status was associated with a worse OS. CONCLUSION: The immunohistochemically assessed level of COX-2 expression does not seem to represent a valuable independent prognostic factor and is not superior to the conventional prognostic factors.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a senioři nad 80 let $7 D000369
- 650 _2
- $a monoklonální protilátky $x metabolismus $7 D000911
- 650 _2
- $a cyklooxygenasa 2 $x biosyntéza $7 D051546
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a regulace genové exprese enzymů $7 D015971
- 650 _2
- $a regulace genové exprese u nádorů $7 D015972
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a imunohistochemie $x metody $7 D007150
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a vývody pankreatu $x enzymologie $x patologie $7 D010183
- 650 _2
- $a nádory slinivky břišní $x enzymologie $x chirurgie $7 D010190
- 650 _2
- $a prognóza $7 D011379
- 650 _2
- $a proporcionální rizikové modely $7 D016016
- 655 _2
- $a srovnávací studie $7 D003160
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Karásek, Petr $7 xx0128590 $u Department of Complex Oncology Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic
- 700 1_
- $a Tomášek, Jiří $7 xx0107945 $u Department of Complex Oncology Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic
- 700 1#
- $a Lenz, Jiří. $7 xx0179491 $u First Department of Pathologic Anatomy, Medical Faculty of Masaryk University and St. Anne's University Hospital, Brno, Czech Republic
- 700 1_
- $a Jarkovský, Jiří, $d 1976- $u Institute of Biostatistics and Analyses, Masaryk University, Brno, Czech Republic $7 stk2008461294
- 700 1_
- $a Dítě, Petr, $d 1941- $7 jn20000400604 $u Department of Gastroenterology, Medical Faculty of Masaryk University and The Faculty Hospital, Brno, Czech Republic
- 773 0_
- $w MED00006918 $t World journal of gastroenterology WJG $x 1007-9327 $g Roč. 16, č. 15 (2010), s. 1879-1884
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/20397266 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y m $z 0
- 990 __
- $a 20120817 $b ABA008
- 991 __
- $a 20200429134608 $b ABA008
- 999 __
- $a ok $b bmc $g 947828 $s 783132
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2010 $b 16 $c 15 $d 1879-1884 $i 1007-9327 $m World journal of gastroenterology $n World J Gastroenterol $x MED00006918
- GRA __
- $a NR9295 $p MZ0
- LZP __
- $a Pubmed-20120817/10/03